What is 1910 Genetics?
Headquartered in Cambridge, Massachusetts, 1910 Genetics operates at the vanguard of the digital biology revolution. The company specializes in identifying and validating therapeutic targets through a sophisticated, AI-driven engine that integrates multi-omics data with high-throughput experimentation. By streamlining the early stages of drug development, 1910 Genetics addresses the inherent inefficiencies in traditional pharmaceutical research, offering a more precise and scalable approach to treating complex diseases. Its market position is bolstered by a focus on genetically validated targets, which significantly reduces the risk profile typically associated with early-stage biotech ventures.
How much funding has 1910 Genetics raised?
1910 Genetics has raised a total of $47.7M across 2 funding rounds:
Series A
$22M
Stock Offering
$25.7M
Series A (2021): $22M with participation from Playground and M12
Stock Issuance/Offering (2021): $25.7M, investors not publicly disclosed
Key Investors in 1910 Genetics
M12
M12, Microsoft's Venture Fund, invests in enterprise software companies primarily in the Series A through C funding stages with a focus on applied AI, business applications, infrastructure, security, and vanguard technologies.
Playground
A venture capital firm specializing in deep tech and early-stage investments, focusing on companies that leverage hardware and software to solve complex global challenges.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for 1910 Genetics?
With the recent capital injection, 1910 Genetics is well-positioned to transition from its foundational research phase into a more robust operational scaling stage. The strategic roadmap likely involves the expansion of its internal pipeline of therapeutic candidates and the potential for high-value partnerships with established pharmaceutical entities. As the company continues to refine its computational models, the focus will shift toward clinical validation and the commercialization of its proprietary platform. Investors will be closely monitoring the firm's ability to translate its AI-driven insights into tangible clinical outcomes, which remains the ultimate benchmark for success in the modern biotech ecosystem.
See full 1910 Genetics company page
